Tag: Ladenburg Thalmann
April 18, 2018
Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Bellicum Pharmaceuticals (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited... February 15, 2018
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced... January 30, 2018
Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering
Auris Medical (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today... January 25, 2018
Eyenovia Announces Pricing of Initial Public Offering
Eyenovia (NASDAQ:EYEN) a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics... January 24, 2018
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a... January 19, 2018
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a...
June 16, 2017